Basecamp › The Benefits, Mapped
Chapter III · The map
The Benefits, Mapped — every waypoint pinned to its evidence tier
A good expedition map distinguishes surveyed ground from rumour. This chapter does the same for bromantane: every benefit area below carries the strongest evidence tier that honestly supports it — and nothing is promoted beyond its tier.
§01Surveyed ground — the clinical tier
Anti-asthenia / anti-fatigue — the strongest waypoint
A 728-patient, 28-centre Russian multicentre trial of ladasten (50–100 mg/day for 28 days) in asthenic disorders with psychoautonomic syndrome: effect apparent from day 3, persisting one month after treatment ended; responder rates of 76.0% (CGI-S) and 90.8% (CGI-I). Sleep–wake normalisation was also observed. Adverse effects in 3% of patients, discontinuation 0.8%, and no serious adverse events at these doses.
Neurasthenia — placebo-controlled
In the comparative placebo-controlled study, ladasten was superior to placebo in both the rate and the degree of asthenia-symptom reduction, combining psychostimulant and anxiolytic action in one profile — and no withdrawal syndrome appeared after discontinuation.
Anxiolytic — without sedation
Anxiolytic efficacy appeared in both trials, and bromantane lacks the hypno-sedative and muscle-relaxant properties of classical anxiolytics. The proposed basis is a GABA-ergic component described in the actoprotector review — hence the dual tier.
No dependence, tolerance, or withdrawal
The neurasthenia RCT recorded no withdrawal after discontinuation; chronic animal administration produced neither dependence nor tolerance. The actoprotector review summarises the profile as an almost complete absence of side effects including withdrawal and hyperstimulation at therapeutic doses.
§02Base-camp measurements — the animal tier
Physical endurance & work capacity
Across 0.5–50 mg/kg, bromantane exceeded the effect of phenamine (amphetamine) by 1.3–1.6× in mouse swimming and rat treadmill tests (Morozov & Kleimenova, 1998) — the headline endurance finding, and the reason the compound drew sport's attention.
Performance in heat; hypoxia recovery
Thermoprotective effects during overheating were documented experimentally (Badyshtov, 1995); the review adds recovery findings under hypoxia and hyperthermia — exactly the "complicated conditions" the Zakusov programme designed for.
Motivation / drive
In rats working through 5-hour operant sessions, bromantane (20 mg/kg) raised the motivational component of behaviour (Morozov, 2000). Human motivation claims go beyond the data — animal tier only.
Immune support
Increased B-cell levels and circulating immune complexes after even a single dose; normalisation of T-cell subpopulations and the CD4/CD8 ratio in chronically stressed mice; lowered pro-inflammatory cytokines (IL-6, IL-17) in an anxious-depression mouse model. No human immune-outcome trials have been found — this waypoint stays at animal tier.
§03Reported from the trail — review & field tier
Mental performance, attention, operator activity
Small human studies summarised in the actoprotector review report improved attention span and stability, complex sensorimotor reaction, and operator-activity parameters — intriguing, but review-level rather than trial-grade.
Recovery after strong exertion
The review records bromantane's use in the Soviet and Russian armies to shorten recovery after strong physical exertion ("though not as widely as bemitil"). No open primary field-trial report has surfaced in English, so this is filed as review-sourced, animal-supported.
Tolerability / low toxicity
Clinically: 3% adverse effects and 0.8% discontinuation across 728 patients, with no serious adverse events; Russian prescribing information lists insomnia and hyperactivation as possible effects. In animals, toxicity appeared only at very high doses (behavioural effects from 30–300 mg/kg; toxic signs above ~5 g/kg), attributed to anticholinergic actions at extreme doses — not clinically relevant. Caveat: nearly all safety data are Russian.
§04The map, on one sheet
| Benefit area | Tier | Anchor |
|---|---|---|
| Anti-asthenia / anti-fatigue | Clinical | 728-patient multicentre trial (PMID 21322821) |
| Neurasthenia | Clinical RCT | Placebo-controlled study (PMID 19491814) |
| Sleep–wake normalisation | Clinical | Observed in the 728-patient trial |
| Anxiolytic without sedation | Clinical Review | Both trials; GABA mechanism per review |
| No dependence / withdrawal / tolerance | Clinical Animal | RCT + chronic animal studies |
| Physical endurance & work capacity | Animal | 1.3–1.6× over amphetamine (PMID 9929819) |
| Heat performance | Animal | Thermoprotection (PMID 7793100) |
| Hypoxia recovery | Review | Actoprotector review (PMC3762282) |
| Mental performance / attention | Human · small studies | Review-summarised operator studies |
| Motivation / drive | Animal | Operant behaviour (PMID 10934588) |
| Recovery after exertion | Review Animal | Military field use per review |
| Immune support | Animal | T-cell / cytokine studies (PMID 24771370) |
| Low toxicity / tolerability | Clinical Animal | 3% AE rate clinically; toxicity only at extreme doses |
Read the map as a mountaineer would: the clinical tier is surveyed ground — walk it freely. The animal tier is a good compass bearing, not a path. And the review tier is a story from a trusted guide — worth hearing, worth verifying.
§05Keep exploring
The machinery behind these waypoints is traced in How It Works; the people who did the discovering are credited in From Soviet Laboratories; and Panacea's own investigation is described in The Panacea Programme.
§06Trending at basecamp
Recent reading from the field — refreshed 2026-07-25 by Panacea Bio Chem.
- Treatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study of ladasten — 728 patients, 2010
- Ladasten in treatment of neurasthenia: comparative clinical study with placebo — 2009
- Effect of bromantane on physical work capacity in animals — Morozov & Kleimenova, 1998
- The complete PubMed record set for bromantane (34 entries) — continuously indexed
§07References for this chapter
- Voznesenskaia TG, Fokina NM, Iakhno NN. Treatment of asthenic disorders in patients with psychoautonomic syndrome. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5 Pt 1):17-26. PMID 21322821
- Neznamov GG, Siuniakov SA, Teleshova SE, et al. Ladasten in treatment of neurasthenia: comparative clinical study with placebo. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(5):20-6. PMID 19491814
- Morozov IS, Kleimenova NN. Effect of bromantane on the physical work capacity of animals. Eksp Klin Farmakol. 1998;61(6):51-3. PMID 9929819
- Badyshtov BA, et al. The thermoprotective action of bromantane during overheating. 1995. PMID 7793100
- Morozov IS, et al. The motivational component of operant behaviour under bromantane. 2000. PMID 10934588
- Tallerova AV, et al. T-cell immunomodulation by bromantane in chronically stressed mice. Bull Exp Biol Med. 2014;156(3):335-7. PMID 24771370 · doi:10.1007/s10517-014-2343-1
- Iezhitsa IN, et al. Toxicological and neurotropic assessment of bromantane. Bull Exp Biol Med. 2002;133(4):380-3. PMID 12124651 · doi:10.1023/A:1016206306875
- Oliynyk S, Oh S. The pharmacology of actoprotectors. Biomol Ther (Seoul). 2012;20(5):446-56. PMC3762282